Glioblastoma multiforme (GBM), the most common and aggressive primary brain tumor, has
a high mortality rate despite extensive efforts to develop new treatments. GBM exhibits both …

There is urgency for the development of nanomaterials that can meet emerging biomedical
needs. Magnetic nanoparticles (MNPs) offer high magnetic moments and surface‐area‐to …

The development of nanoparticles (NPs) for use in all facets of oncological disease
detection and therapy has shown great progress over the past two decades. NPs have been …

The microenvironment characteristics of solid tumors, renowned as barriers that harshly
impeded many drug-delivery approaches, were precisely studied, investigated, categorized …

The current achievements in treating glioblastoma (GBM) patients are not sufficient because
many challenges exist, such as tumor heterogeneity, the blood brain barrier, glioma stem …

Peptide–and protein–nanoparticle conjugates have emerged as powerful tools for
biomedical applications, enabling the treatment, diagnosis, and prevention of disease. In …

Due to the ability of the blood–brain barrier (BBB) to prevent the entry of drugs into the brain,
it is a challenge to treat central nervous system disorders pharmacologically. The …

Introduction The targeted delivery of anticancer agents to tumor is a major challenge
because most of the drugs show off-target effect resulting in nonspecific cell death …

Glioblastoma (GBM) is a highly malignant brain tumor characterized by a heterogeneous
population of genetically unstable and highly infiltrative cells that are resistant to …

Magnetic nanomaterials belong to a class of highly-functionalizable tools for cancer therapy
owing to their intrinsic magnetic properties and multifunctional design that provides a …